Controlling drug-to-antibody ratio and scalable reactors are key to reliable antibody-drug conjugate manufacturing success.

A new wave of antibody-targeted anticancer therapies is showing great clinical promise, with the potential to transform cancer treatment. These antibody-drug conjugates (ADCs) are multicomponent ...